Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)

Reports Q2 revenue $5.2M, consensus $9.5M. “We firmly believe Voyager’s science has the potential to drive transformative neurotherapeutics, and that the efficiencies we have created this year give us the runway to prove it,” said Alfred W. Sandrock, Jr., Chief Executive Officer of Voyager. “We expect to have four programs in the clinic next year, and with our runway now extended into 2028, we are positioned to get well beyond multiple potential clinical inflection points.”